Replies to post #4730 on DARA BioSciences, Inc. (DARA)

[bioresearcher]

Thank you tassitano, see this:

You might think it is strange what i am saying, but the fact is that as an investor i am not worry about orphan drug designation status.

I think if DARA gets orphan drug designation,it will be good for one side, but the size of the market are smaller than if they try commercialize in a large scale population where the drug could really wok well.

Any of them are good for the stock...if i were the management i would apply to FDA to get that designation, meanwhile i will be doing contacts to parternership the drug, their trials and commercialization.

And i know that the company is in contact with others,so i think they are expecting an FDA decision to anounce what game they are going to play and with whom...

DARA has also an advantage, they have products in the market...while others are only in early stages, DARA was able to advance to the commercialization of products into the market..and i believe sales will encrease next quarters.

As an investor i think the reward could be bigger than the risk at this lower level prices.

My personal opinion,

Regards